Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results

被引：1
|
作者：
Yuan, X-J. [1 ]
Zhang, X. [1 ]
Li, Q. [2 ]
Wang, Z. [2 ]
Li, C. [3 ]
Liu, Y. [4 ]
Ge, X. [5 ]
Zhao, J. [6 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Paediat Hematol Oncol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Plast & Reconstruct Surg, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
[3] AstraZeneca Global R&D China Co Ltd, Hematol Oncol, Shanghai, Peoples R China
[4] AstraZeneca Global R&D China Co Ltd, Biometr, Shanghai, Peoples R China
[5] AstraZeneca Global R&D China Co Ltd, Clin Safety, Shanghai, Peoples R China
[6] AstraZeneca Global R&D China Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402P
引用
收藏
页码：S1599 / S1599
页数：1
相关论文
共 50 条
  • [21] Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas
    Stein Schalkwijk
    Li Zhou
    Sarit Cohen‐Rabbie
    Lokesh Jain
    Tomoko Freshwater
    Karen So
    Zhongqing He
    Ioanna Gioni
    Helen Tomkinson
    Karthick Vishwanathan
    Diansong Zhou
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 189 - 202
  • [22] TOLERABILITY OF THE MTOR INHIBITOR SIROLIMUS IN A PHASE II STUDY FOR NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMAS: A NEUROFIBROMATOSIS CONSORTIUM STUDY
    Weiss, B.
    Widemann, B. C.
    Cantor, A.
    Perentesis, J.
    Vinks, A.
    Ullrich, N.
    Gutmann, D.
    Korp, B.
    Packer, R.
    Fisher, M. J.
    NEURO-ONCOLOGY, 2010, 12 (06) : II85 - II85
  • [23] PREDICTORS OF PLEXIFORM NEUROFIBROMA (PN) GROWTH IN PATIENTS WITH NEUROFIBROMATOSIS 1 (NF1)
    Akshintala, Srivandana
    Dombi, Eva
    Baldwin, Andrea
    Gillespie, Andy
    Goodspeed, Wendy
    Goodwin, Anne
    Whitcomb, Patricia
    Steinberg, Seth
    Widemann, Brigitte
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S32 - S33
  • [24] A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1)
    Gupta, A
    Cohen, BH
    Ruggieri, P
    Packer, RJ
    Phillips, P
    NEUROLOGY, 2000, 54 (07) : A12 - A13
  • [25] Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis
    Han, Yahui
    Li, Biyun
    Yu, Xiaokun
    Liu, Jianing
    Zhao, Wei
    Zhang, Da
    Zhang, Jiao
    JOURNAL OF NEUROLOGY, 2024, 271 (05) : 2379 - 2389
  • [26] Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
    Gross, Andrea M.
    Dombi, Eva
    Wolters, Pamela L.
    Baldwin, Andrea
    Dufek, Anne
    Herrera, Kailey
    Martin, Staci
    Derdak, Joanne
    Heisey, Kara S.
    Whitcomb, Patricia M.
    Steinberg, Seth M.
    Venzon, David J.
    Fisher, Michael J.
    Kim, AeRang
    Bornhorst, Miriam
    Weiss, Brian D.
    Blakeley, Jaishri O.
    Smith, Malcolm A.
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2023, 25 (10) : 1883 - 1894
  • [27] Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis
    Yahui Han
    Biyun Li
    Xiaokun Yu
    Jianing Liu
    Wei Zhao
    Da Zhang
    Jiao Zhang
    Journal of Neurology, 2024, 271 : 2379 - 2389
  • [28] Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma
    Kim, Hyery
    Yoon, Hee Mang
    Kim, Eun Key
    Ra, Young Shin
    Kim, Hyo-Won
    Yum, Mi-Sun
    Kim, Min-Jee
    Baek, Jae Suk
    Sung, Yu Sub
    Lee, Sang Min
    Lim, Hyeong-Seok
    Lee, Byung Joo
    Lim, Hyun Taek
    Kim, Dohyung
    Yoon, Jihee
    Bae, Hyunwoo
    Hwang, Soojin
    Choi, Yun-Ha
    Kim, Kyung Ah
    Choi, In Hee
    Lee, Seung Won
    Park, Su-Jung
    Lee, Beom Hee
    NEURO-ONCOLOGY, 2024,
  • [29] Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).
    Hittson, Lauren
    Glod, John
    Amaya, Melissa
    Derdak, Joanne
    Widemann, Brigitte C.
    Kaplan, Rosandra N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline
    Volonte, Martina
    Isoletta, Eugenio
    Gordon, Shaul
    Foiadelli, Thomas
    Bassanese, Francesco
    Rossi, Alessandra
    Marseglia, Gian Luigi
    Savasta, Salvatore
    Brazzelli, Valeria
    DERMATOLOGIC THERAPY, 2022, 35 (08)
12345